Federal contract award
75A50124C00003
DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AJ11 — GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $5.6M |
| Current contract value | $5.6M |
| Potential contract value / ceiling | $38.2M |
| Start date | Mar 20, 2024 |
| Current end date | Dec 31, 2032 |
| Potential end date | Dec 31, 2032 |
| Latest award activity | Aug 12, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 12, 2026 | P00012 | $2.6M | THE PURPOSE OF THIS SUPPLEMENTAL AGREEMENT IS TO: 1) INCORPORATE MANDATORY CLAUSES. 2) EXERCISE AND FUND CLIN 0002 - OPTION PERIOD 1 IN THE AMOUNT OF $2,622,474.00. 3) UPDATE ATTACHMENT 1 - STATEMENT OF WORK. |
| May 12, 2026 | P00011 | $0 | THE PURPOSE OF THIS NO-COST MODIFICATION IS TO REVISE ARTICLE G.7. INDIRECT COST RATE AND 52.222-90 ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS. |
| Jun 24, 2025 | P00010 | $0 | THE PURPOSE OF THE UNILATERAL NO COST MODIFICATION IS TO DESIGNATE THE ALTERNATE COR DR. SAIMA ZAMAN AS THE PRIMARY COR IAW THE EXECUTED COR DESIGNATION MEMORANDUM. DR. CAROL DIAZ-DIAZ WILL ASSUME THE POSITION OF ALTERNATE COR. |
| May 28, 2025 | P00009 | $43.3K | SUPPLEMENTAL AGREEMENT TO FUND CLIN 0001 AND UPDATE STATEMENT OF WORK. |
| Apr 22, 2025 | P00008 | $0 | NO COST MODIFICATION TO INCORPORATE APPROVED RATES IN SECTION G.7. INDIRECT COST RATES. |
| Apr 10, 2025 | P00007 | $0 | NO COST MODIFICATION IS SO CONTRACT NO. 75A50124C00003 CAN RECEIVE GOVERNMENT FURNISHED PROPERTY (GFP) FROM CONTRACT NO. 75A50122C00076 AND CONTRACT NO. HHSO100201600021C. |
| Mar 7, 2025 | P00006 | $0 | NO COST MODIFICATION TO ADD A QUALITY AGREEMENT, REVISE THE STATEMENT OF WORK, AND ADD EXECUTIVE ORDER FAR CLAUSE CHANGES. |
| Jan 13, 2025 | P00005 | $0 | UNILATERAL NO COST MODIFICATION TO DESIGNATE THE ALTERNATE COR DR. CAROL DIAZ-DIAZ AS THE PRIMARY COR. SAIMA ZAMAN WILL TEMPORARILY ASSUME THE ALTERNATE COR POSITION. |
| Dec 13, 2024 | P00004 | $0 | NO COST MODIFICATION TO TRANSFER GOVERNMENT FURNISHED PROPERTY UNDER BARDA CONTRACT NUMBER 75A50122C00076 TO BARDA CONTRACT NUMBER 75A50124C00003. |
| Dec 3, 2024 | P00003 | $0 | NO COST MODIFICATION TO TRANSFER GOVERNMENT FURNISHED PROPERTY UNDER BARDA CONTRACT NUMBER 75A50124C00003 TO BARDA CONTRACT NUMBER HHS100201600021C. |
| Oct 1, 2024 | P00002 | $0 | NO COST MODIFICATION TO TRANSFER GOVERNMENT FURNISHED PROPERTY UNDER BARDA CONTRACT NO. 75A50122C00076 TO BARDA CONTRACT NO. 75A50124C00003. |
| Aug 13, 2024 | P00001 | $0 | NO COST MODIFICATION TO REVISE INDIRECT RATES IN SECTION G.7. |
| Mar 19, 2024 | 0 | $3.0M | DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS |
Estimated positioning window
Dec 31, 2031 – Jun 30, 2032
35/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 35/100. Available recorded signals: 30 points.
- Contract end 2032-12-31 (2259 days from calculation)
- +5 points
- 1 historical awards in this buyer and category group
- +0 points
- 13 recorded award transactions
- +10 points
- Latest award action: 2026-08-12
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.